Mutabilis and 4SC Collaborate
Martinsried/Paris - 4SC AG, a German drug discovery and development company and Mutabilis S.A., a French biotech company, focusing on the discovery of new therapeutic approaches for controlling hospital-acquired infections signed a research partnership. “We are pleased to start this collaboration with 4SC, which, we believe will give us a unique and fast capability of identifying lead compounds for our targets,” said Sonia Escaich, CEO of Mutabilis. Both companys aim to identify new molecules as a basis for drug discovery against an undisclosed target provided by Mutabilis. 4SC will use its proprietary virtual high throughput screening technology 4Scan® to screen a database of 4.6 million small organic molecules in order to identify new active compounds that bind to the specific target. Mutabilis will then receive a selection of best ranked molecules for biological testing and further evaluation. In return, 4SC receives undisclosed research funding and will be eligible for milestone payments. “We are delighted that Mutabilis has chosen 4SC for this research partnership,” commented Dr. Ulrich Dauer, CEO of 4SC. “This deal is yet another validation of 4SC's technology platform.”4SC was founded in 1997 and today employs 60 people in Martinsried near Munich.